Facebook
X
LinkedIn
Forward
Virtual 6th Annual Conference on Psychedelics and Psychedelic Medicine
We invite you to join us Virtually for our 6th Annual Conference on Psychedelics and Psychedelic Medicine!
Please Note: The conference will be held in Eastern Daylight Time (EDT)
Course Director Franklin King, MD, presents this annual conference as a clinically focused examination of the rapidly evolving field of psychedelic medicine. The program offers up-to-date overviews and critical discussions of current research in psychedelics and psychedelic-assisted therapies, with a clear emphasis on clinical evidence and real-world practice. Sessions will explore proposed mechanisms of action—including pharmacology, neuroscience, and psychodynamic frameworks—while grounding these concepts in the treatment of specific clinical conditions such as depression, PTSD, and substance use disorders. In addition, expert panels and presentations will address ethical considerations, historical context, cultural perspectives, and the role of plant-based medicines, providing clinicians with a balanced, academically rigorous view of this emerging therapeutic landscape.
You will receive an email communication (to the email registered to your MGH Psychiatry Academy account) as we get closer to the conference date with details on the Zoom instructions and attending virtually.
Pricing
MDs/Doctoral-Level Professionals:
Super Early Bird (on or before June 15, 2026): $525
Early Bird (on or before July 31, 2026): $575
Regular Registration (after July 31, 2026): $600
Other Clinicians:
Super Early Bird (on or before June 15, 2026): $425
Early Bird (on or before July 31, 2026): $475
Regular Registration (after July 31, 2026): $500
Other Professionals: $150.00
Trainees/Students: $100.00
Conference Recordings Access
Recordings of all conference sessions will be made available to registered attendees. Once released, recordings will be accessible for 30 days following the conclusion of the conference.
E-Syllabus
We provide all attendees with completely free access to all slide presentations in digital PDF format prior to the conference. This is an environmentally friendly alternative and helps keep costs lower for all attendees. The e-syllabus will be available for 30 days after the conference.
Livestream Troubleshooting Tips.pdf
Cancellation Policy
A refund minus a $100.00 administrative fee will be issued for refund requests received by October 3, 2026. No refunds will be issued for refund requests made after October 3, 2026. Payments made may not be applied to future conferences or other educational activities. There are no exceptions to these policies.
Target Audience
This program is designed for clinicians and researchers across various disciplines who are interested in deepening their understanding of psychedelics, both theoretically and practically. It is open to mental health practitioners such as psychiatrists, psychiatric nurse practitioners, social workers, and clinical psychologists, as well as professionals from other fields who are curious about the applications of psychedelics in clinical and research settings.
Learning Objectives
By the end of this program, participants will be able to:
- Compare different models of psychedelic-assisted psychotherapy (eg, psycholytic vs psychedelic).
- Identify the potential risks of psychedelic-assisted therapies.
- Identify the training and education programs and protocols for Psychedelic Assisted therapies.
- Explain the neuropsychopharmacology of classical psychedelics, as well as atypical psychedelics such as ketamine and empathogens such as MDMA.
- Identify the neuropsychopharmacology of classical psychedelics, as well as atypical psychedelics such as ketamine and empathogens such as MDMA.
- Identify hypotheses for mechanisms of action of psychedelics on the brain, based on recent neuroimaging studies.
- Identify contemporary medico-cultural issues within psychedelic research.
- Critique contemporary medico-cultural issues within psychedelic research, including race-based structural biases and epistemic injustice.
- Identify race-based structural biases and epistemic injustice in psychedelic research.
- Assess potential applications of psychedelic-assisted therapy in extra-psychiatric fields, such as within palliative care and spirituality, as well as within medicine, such as for pain and immunomodulation.
- Discuss the ethical considerations and frameworks necessary for conducting research with psychedelic substances.
- Analyze the current regulatory landscape for psychedelic therapies and their implications for clinical practice.
Accreditation
Check Back Soon for Accreditation Information.
Please come back later for the Agenda.
Check Back Soon for Faculty Information.
Course Director:
Franklin King, MD
Director, Training and Education, Center for Neuroscience of Psychedelics, Massachusetts General Hospital
Instructor in Psychiatry, Harvard Medical School